Long-term results of treatment of patients with newly detected pulmonary tuberculosis

Author:

Pavlova M. V.1ORCID,Lushina O. V.2ORCID,Anisimova A. I.1ORCID,Archakova L. I.1ORCID,Yablonskiy P. K.3ORCID

Affiliation:

1. Saint-Petersburg State Research Institute of Phthisiopulmonology

2. Saint-Petersburg State Research Institute of Phthisiopulmonology; Interdistrict Petrograd-Primorsky TB Dispensary No. 3

3. Saint-Petersburg State Research Institute of Phthisiopulmonology; St Petersburg State University

Abstract

Introduction. The article is devoted to the effectiveness of the treatment of pulmonary tuberculosis with multiple (MDR) and broad drug resistance (XDR) M. tuberculosis (MBT) in patients after the end of the main course of treatment (intensive and continuation phase), which were observed with clinical cure in 3rd dispensary registration group.Aim. To study the long-term results of treatment of newly diagnosed patients with pulmonary tuberculosis with MDR and XDR MBT with the determination of significant risk factors for relapse in a megalopolis.Materials and methods. The main course of treatment was completed by 119 newly diagnosed patients with pulmonary tuberculosis with MDR or XDR TB for the period from 2013 to 2019, who were treated in anti-tuberculosis hospitals in St. Petersburg and outpatient in St. Petersburg Interdistrict Petrograd-Primorsky TB Dispensary No. 3. The patients were divided into two groups: the main group (MG) consisted of 40 people who received treatment regimens that included drugs (thioureidoiminomethylpyridinium perchlorate (perchlosone, bedaquiline, linezolid ), the control group (CG) – 79 people who received who received standard therapy, without the above drugs. The groups are comparable in clinical, radiological and bacteriological characteristics. The course of treatment was found effective in 86 (72.3%): in MG – in 34 (85.0%) people, in CG – in 52 (65.8%) people, p < 0.01. These 86 patients were transferred to the 3rd group of dispensary registration with a diagnosis of “clinical cure”.Results. Adverse treatment outcomes were analyzed, including the causes of tuberculosis recurrence. The use of drugs (perchlosone, bedaquiline, linezolid) in the complex chemotherapy of tuberculosis with MDR and XDR MBT increases the effectiveness of treatment of patients and significantly less often they have a recurrence of pulmonary tuberculosis (12.5%), compared with the group without the use of these drugs (27.8%). The most significant risk factors for relapses of drug-resistant tuberculosis: the preservation of residual cavities in the absence of bacterial excretion at the end of the main c male gender, concomitant pathology (HIV infection), past incarceration, late detection of the disease and destructive forms of tuberculosis.Conclusions. The main course of therapy was found to be effective in 86 (72.3%) in patients with MG – in 34 (85.0%) people, in CG – in 52 (65.8%) people, p < 0.01. All the patients who completed the course of therapy were transferred to the 3rd group of dispensary registration with a diagnosis of “clinical cure”. Relapses of the disease occurred much less frequently in patients receiving perchlozon, bedaquiline, linezolid in complex therapy compared with the control group.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference29 articles.

1. Stavitskaya NV, Felker IG, Zhukova EM, Tlif АI, Doktorova NP, Kudlay DА. The multivariate analysis of results of bedaquiline use in the therapy of MDR/XDR pulmonary tuberculosis. Tuberculosis and Lung Diseases. 2020;98(7):56–62. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-7-56-62.

2. Tikhonova LYu, Sokolova VV, Tarasyuk IA, Ekimenko AM, Cherenkova MA, Kudlay DA. Experience of treatment of multiple drug resistant tuberculosis patients with bedaquiline in Amur Region. Tuberculosis and Lung Diseases. 2018;96(6):45–50. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-6-45-50.

3. Golubchikov PN, Kruk EA, Mishustin SP, Petrenko TI, Kudlay DA. Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results. Tuberculosis and Lung Diseases. 2019;97(8):38–45. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-8-38-45.

4. Nunn AJ, Rusen ID, Van Deun A, Torrea G, Phillips PPJ, Chiang Chen-Yuan et al. Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients withmulti-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial. Trials. 2014;9(15):353. https://doi.org/10.1186/1745-6215-15-353.

5. Lee M, Mok J, Kim DK, Shim TS, Koh W-J, Jeon D et al. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Trials. 2019;20(1):57. https://doi.org/10.1186/s13063-018-3053-1.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3